All Cancer articles – Page 22
-
NewsNew methodologies to find microbiome biomarkers
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
-
NewsFirst animal model for Kaposi sarcoma developed
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
-
NewsHow tumours prevent formation of immune responses
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
-
NewsMini-colons reveal complex process of tumorigenesis ex vivo
The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
-
NewsNew single-cell lipidomics method may unlock cancer treatments
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
-
NewsTargeting RAS to overcome FLT3 AML drug resistance
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
-
NewsDrug-loaded 3D printed films could revolutionise liver cancer treatment
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
-
NewsExplaining uveal melanoma’s resistance to conventional immunotherapies
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
-
NewsNew screening method for HPV-positive head and neck cancer
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
-
ArticleThe immune system’s role in lung cancer risk
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
-
NewsElucidating the mechanism that initiates cancer cachexia
The new findings could lead to new therapeutics and a method to diagnose pancreatic cancer earlier, improving its prognosis.
-
NewsMelanoma tumours produce altBRAFs by genomic deletions
The discovery that genomic deletions cause altBRAFs can help develop new therapies to overcome drug resistance in BRAF-mutant melanoma.
-
NewsProteogenomic signatures: metastatic prostate cancer risk
Mutation signatures and recurrent copy number alterations correlated with a higher risk for disease progression.
-
NewsLink identified between bacteria and cancer treatment efficacy
Researchers mapped the bacteria present in over 4000 metastatic tumour biopsies, which could enable the exploration of new treatments.
-
News
B-ALL: combination therapy effectively controls high-risk subtypes
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
-
Article
HIF inhibition: a potential therapeutic approach for cancers
In this Q&A, Curve Therapeutic’s Chief Scientific Officer Professor Ali Tavassoli discusses how dual HIF inhibition could combat solid tumours.
-
ArticleUsing AI to predict metastatic behaviour of NSCLC
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
-
NewsCombatting T-cell tumours with antibody drug conjugates
One treatment with the anti-TRBC1-SG3249 ADC combination saw cancer elimination within seven days in mouse models.
-
NewsReversing malignant cancer cells to a normal state
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
-
News
MUTYH variants implicated in a broader range of cancers
The discovery that one missing copy of MUTYH could increase the risk of cancers may lead to therapeutics against solid tumours.